DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

D.h.e. 45 (Dihydroergotamine Mesylate) - Indications and Dosage

 
 



INDICATIONS AND USAGE

D.H.E. 45® (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

DOSAGE AND ADMINISTRATION

D.H.E. 45® (dihydroergotamine mesylate) Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. The dose can be repeated, as needed, at 1 hour intervals to a total dose of 3 mL for intramuscular or subcutaneous delivery or 2 mL for intravenous delivery in a 24 hour period. The total weekly dosage should not exceed 6 mL. D.H.E. 45® (dihydroergotamine mesylate) Injection, USP, should not be used for chronic daily administration.

HOW SUPPLIED

D.H.E. 45 ® (dihydroergotamine mesylate) Injection, USP

Available as a clear, colorless, sterile solution in single 1 mL sterile ampuls containing 1 mg of dihydroergotamine mesylate per mL, in packages of 10 (NDC 0078-0041-01).

Store below 25°C (77°F), in light-resistant containers.

Do not refrigerate or freeze.

To assure constant potency, protect the ampuls from light and heat. Administer only if clear and colorless.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017